AstraZeneca announces baxdrostat met primary endpoint in Bax24 Phase III trial

Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure, SBP, compared with placebo at 12 weeks. Patients with treatment-resistant hypertension, rHTN, received baxdrostat 2mg or placebo on top of standard of care. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events. Baxdrostat met the primary endpoint in the Bax24 Phase III trial, delivering clinically meaningful and consistent blood pressure reductions in patients with treatment-resistant hypertension. At 12 weeks, the placebo-adjusted reduction in ambulatory 24-hour average SBP was 14.0 mmHg. Baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial.